The Company
NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.
NanoGhost offers a novel, versatile, and highly selective targeted drug delivery platform for the treatment of oncological and immunological diseases.
NanoGhosts can be loaded with various drug types (i.e. small molecules, DNA, RNA, peptides, proteins), preserve MSC’s tropism to cancer cells, and selectively penetrate tumors (as demonstrated in various preclinical models of solid tumor, including brain tumors while crossing the BBB and pancreatic cancer), leading to a major reduction in tumor size and prolonged survival following a single treatment.
Management & Board of Directors
Marcelle Machluf
Founder & Director
-
PhD
-
Dean of the faculty of Biotechnology & Food Engineering
-
President of the Israeli Chapter of the Controlled Release Society (ICRS)
-
Director (InsuLine Medical) Former SAB member (GluSense, Beta-O2)
Yonatan Malca
CEO
-
MA
-
CEO at DNA Biomedical Solutions Ltd. (TASE:DNA) life sciences holding company
-
Director at Entera Bio Ltd. Oral Delivery of Large Molecules (NASDAQ:ENTX)
-
Director at BeamMed Ltd. develop and market advanced ultrasound devices for bone density assessment
Osnat Bohana Kashtan
VP R&D
-
PhD, MBA
-
11 years of pharma experience leading development of small molecule, peptide and cell-based therapies for immune disorders, cancer and neurodegenerative diseases
-
Served as the director of R&D at Cell Cure Neurosciences
-
Led a Phase III clinical program at BiolineRx
-
Postdoctoral fellowship in oncology, Johns Hopkins SOM, MD, USA
-
PhD in Cancer Immunology, TAU, Israel